A Discussion of Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

Hosted by William H. Sauer, MD, FHRS, CCDS
Article Information:

**Article for Discussion:** Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

**Authors:** Linda P.T. Joosten, MD, Sander van Doorn, MD, PhD, Peter M. van de Ven, PhD, Bart T.G. Köhlen, Melchior C. Nierman, MD, PhD, Huiberdina L. Koek, MD, PhD, Martin E.W. Hemels, MD, PhD, Menno V. Huisman, MD, PhD, Marieke Kruip, MD, PhD, Laura M. Faber, MD, PhD, Nynke M. Wiersma, MD, Wim F., Rob Fijnheer, MD, PhD, Henk J. Adriaansen, MD, PhD, Kit C. Roes, PhD, Arno W. Hoes, MD, PhD, Frans H. Rutten MD, PhD, Geert-Jan Geersing MD, PhD

**Publication:** Circulation: AHA Journals
Today’s Host

William H. Sauer, MD, FHRSD, CCDS
Brigham and Women's Hospital
Today’s Contributors:

Erik Andrews, MD, MPH
Brigham and Women's Hospital

Christian Thomas Ruff, MD, MPH
Brigham and Women's Hospital
Disclosures:

William H. Sauer, MD, FHRS, CCDS

- Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific
- Research: Medtronic

Erik Andrews, MD, MPH

- Nothing to disclose.

Christian Thomas Ruff, MD, MPH

- Honoraria/Speaking/Consulting: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals
- Research: Daiichi, MedImmune
Thank you!